Researchers found that a new drug candidate, UDP-003, can help the body excrete a harmful cholesterol derivative called 7-ketocholesterol (7KC). This discovery was made during a Phase 1 clinical trial presented at the American Heart Association’s recent conference. The study showed that participants could effectively mobilize and eliminate 7KC through urine, which is significant for those concerned about heart health and cholesterol levels.

This finding matters for your health because 7KC is linked to cardiovascular diseases and may contribute to plaque buildup in arteries. By enhancing the excretion of this compound, UDP-003 could potentially help people manage their cholesterol levels better and reduce their risk of heart-related issues. The trial involved a small group of participants, and the results indicated that the drug was safe, with no serious side effects reported, making it a promising option for future heart health treatments.

The evidence comes from a first-in-human study that was randomized and double-blind, meaning neither the participants nor the researchers knew who received the drug or a placebo. While the results are encouraging, they are still in the early stages. The company plans to conduct a larger Phase 2 trial in 2026 to further investigate the drug’s effectiveness in reducing arterial plaque, which is a key factor in heart disease.

Source: longevity.technology